Last reviewed · How we verify

NCT03725124

Family Planning in Inflammatory Bowel Disease

Completed Last updated 9 September 2020
What this trial tests

trial testing Interview in Inflammatory Bowel Diseases in 31 participants. Completed in 31 January 2020.

Timeline
26 July 2018
Primary endpoint
31 January 2020
31 January 2020

Quick facts

Lead sponsorThe Royal Wolverhampton Hospitals NHS Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment31
Start date26 July 2018
Primary completion31 January 2020
Estimated completion31 January 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

The Royal Wolverhampton Hospitals NHS Trust

Who can join

Adults 18 to 55, any sex, with Inflammatory Bowel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study explores the lived experiences of family planning for women with inflammatory bowel disease (IBD) and their partners during the reproductive stages of pre-conception, pregnancy and the postnatal period through qualitative interviews. Insights from existing literature alongside findings from interviews and focus groups with patients and healthcare providers to develop an intervention to address the issues and support needs as identified by study participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interview

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other The Royal Wolverhampton Hospitals NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing